Bioventus Inc (NASDAQ: BVS) has experienced a rise in its stock price by 0.51 compared to its previous closing price of 7.78. However, the company has seen a gain of 3.30% in its stock price over the last five trading days. zacks.com reported 2025-04-17 that Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration’s healthcare policies.
Is It Worth Investing in Bioventus Inc (NASDAQ: BVS) Right Now?
Moreover, the 36-month beta value for BVS is 0.99. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BVS is 45.16M and currently, short sellers hold a 1.64% of that float. On April 18, 2025, BVS’s average trading volume was 324.06K shares.
BVS’s Market Performance
BVS’s stock has seen a 3.30% increase for the week, with a -21.25% drop in the past month and a -22.65% fall in the past quarter. The volatility ratio for the week is 6.29%, and the volatility levels for the past 30 days are at 6.63% for Bioventus Inc The simple moving average for the last 20 days is -8.93% for BVS’s stock, with a simple moving average of -22.21% for the last 200 days.
Analysts’ Opinion of BVS
Many brokerage firms have already submitted their reports for BVS stocks, with JP Morgan repeating the rating for BVS by listing it as a “Neutral.” The predicted price for BVS in the upcoming period, according to JP Morgan is $13 based on the research report published on December 17, 2024 of the previous year 2024.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see BVS reach a price target of $7. The rating they have provided for BVS stocks is “Buy” according to the report published on December 07th, 2023.
Craig Hallum gave a rating of “Buy” to BVS, setting the target price at $6 in the report published on August 09th of the previous year.
BVS Trading at -17.43% from the 50-Day Moving Average
After a stumble in the market that brought BVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.62% of loss for the given period.
Volatility was left at 6.63%, however, over the last 30 days, the volatility rate increased by 6.29%, as shares sank -19.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.23% lower at present.
During the last 5 trading sessions, BVS rose by +3.30%, which changed the moving average for the period of 200-days by +36.47% in comparison to the 20-day moving average, which settled at $8.59. In addition, Bioventus Inc saw -25.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BVS starting from Singleton Mark Leonard, who sale 3,875 shares at the price of $7.57 back on Apr 11 ’25. After this action, Singleton Mark Leonard now owns 141,088 shares of Bioventus Inc, valued at $29,334 using the latest closing price.
D’Adamio Anthony, the SVP & General Counsel of Bioventus Inc, sale 2,958 shares at $7.57 during a trade that took place back on Apr 11 ’25, which means that D’Adamio Anthony is holding 131,416 shares at $22,392 based on the most recent closing price.
Stock Fundamentals for BVS
Current profitability levels for the company are sitting at:
- -0.02 for the present operating margin
- 0.68 for the gross margin
The net margin for Bioventus Inc stands at -0.06. The total capital return value is set at -0.02. Equity return is now at value -20.86, with -4.36 for asset returns.
Based on Bioventus Inc (BVS), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at 1.42. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -0.31.
Currently, EBITDA for the company is -49.55 million with net debt to EBITDA at -0.5. When we switch over and look at the enterprise to sales, we see a ratio of 0.88. The receivables turnover for the company is 4.5for trailing twelve months and the total asset turnover is 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.31.
Conclusion
To wrap up, the performance of Bioventus Inc (BVS) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
